Intrexon | XON - Gross Profit On Sales


Intrexon reported $-297K in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.89B 415M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.61B 225M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
Intrexon USD -297K 167K Jun/2024
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
MacroGenics USD 31.11M 30.14M Dec/2025
MannKind USD 78.31M 76.21M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Veracyte USD 101.97M 10.69M Dec/2025
Xencor USD 21M 22.61M Sep/2025